Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:IOVA News 3 November 2025 - 23 December 2025

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics shares jumped 12.1% to close at $2.78 on Dec. 22, with pre-market trading near $2.80. Short interest stands at 33.4% of the float, or about 118.94 million shares, according to MarketBeat. Barclays raised its price target to $10 and kept an Overweight rating. Iovance also announced inducement stock options for four new employees at a $2.46 exercise price.
23 December 2025
Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Company Overview: Pioneering TIL Therapy in Oncology Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte (TIL) therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab, then reinfused to attack cancer. This approach, originally pioneered by NCI’s Dr. Steven Rosenberg in the 1980s, finally reached fruition when Iovance’s lifileucel (brand name Amtagvi) earned FDA approval in 2024 as the first-ever TIL therapy (and the first cellular therapy for any solid tumor)cancer.gov. Lifileucel is indicated for unresectable or metastatic melanoma that has progressed after standard immunotherapies (e.g.
3 November 2025

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 08.02.2026

8 February 2026
LIVEMarkets rolling coverageStarted: February 8, 2026, 12:00 AM ESTUpdated: February 8, 2026, 12:53 AM EST Australian Shares Set for Volatile Earnings Season Amid Market Sensitivity February 8, 2026, 12:49 AM EST. **Australian stock markets** face heightened volatility as earnings season kicks off with little room for error. Analysts warn that even a **1% earnings miss** could trigger sharp price swings, stripping away previous insulation from market shocks. This turbulence reflects the removal of 'shock absorbers' in share prices, signaling an unpredictable three weeks ahead for investors. Anthony Macdonald, business journalist and Chanticleer columnist, forecasts significant fluctuations likely exceeding historical norms.
Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

8 February 2026
Tower Semiconductor shares rose 7.7% to $139.04 Friday after announcing a collaboration with Nvidia on AI data-center networking. The stock touched $141 intraday and gained another 1% after hours. Investors await Tower’s Feb. 11 earnings for details on its silicon photonics work. No financial terms or shipment timeline were disclosed.
Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Longsys disclosed new guarantees for a 100 million yuan Hong Kong loan and a $9 million Brazil credit line, bringing its total approved guarantee quota to 11 billion yuan and outstanding guarantees to 5.81 billion yuan. The company said all guarantees are for consolidated subsidiaries and within approved limits. Shares closed at 288 yuan Friday, down 1.6%. China inflation and credit data are due this week.
MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop